Therapeutic Response

v::ALK status confers therapeutic sensitivity to Atezolizumab in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Tecentriq (atezolizumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to atezolizumab for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving atezolizumab.
Atezolizumab 1680mg Monotherapy - 28 Day. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. The regimen further states that patients with EGFR mutations or an ALK fusion oncogene are required to have received prior tyrosine kinase inhibitor therapy.
Tecentriq (atezolizumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving atezolizumab.
Atezolizumab Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. The regimen further states that patients with EGFR mutations or an ALK fusion oncogene are required to have received prior tyrosine kinase inhibitor therapy.